Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

ABSTRACT:

Background

Prostate cancer (PCa) molecular subtypes have been defined by essentially mutually exclusive events, including ETS gene fusions (most commonly involving ERG) and SPINK1 overexpression. Clinical assessment may aid in disease stratification, complementing available prognostic tests.

Objective

To determine the analytical validity and clinicopatholgic associations of microarray-based molecular subtyping.

Design, setting, and participants

We analyzed Affymetrix GeneChip expression profiles for 1577 patients from eight radical prostatectomy cohorts, including 1351 cases assessed using the Decipher prognostic assay (GenomeDx Biosciences, San Diego, CA, USA) performed in a laboratory with Clinical Laboratory Improvements Amendment certification. A microarray-based

SUBMITTER: Tomlins SA 

PROVIDER: S-EPMC4562381 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature